Clinical Trial Update: An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa [Phase 2]

View source ↗

Summary

A Phase 2 open-label extension study evaluating the safety and tolerability of QR-421a in retinitis pigmentosa and Usher syndrome type 2 was terminated, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa
• Usher Syndrome Type

Drugs mentioned

• QR-421a

Snippet

Sponsor: Laboratoires Thea | Conditions: Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 | Status: TERMINATED | Results posted: 2022-12-27